

Avita Medical Presents Research Demonstrating Treatment Power of ReCell® in Burns

Academic Papers Presented at 16th European Burns Association Congress

Northridge, CA and Cambridge, United Kingdom, 27 October 2015 — Avita Medical Ltd. (ASX: [AVH](#)), (OTCQX: [AVMXY](#)), a medical device company specializing in the treatment of wounds and skin defects, today announced the publication of three academic papers that further demonstrate ReCell®'s effectiveness for triggering healing in burns, and helping with scar revision and repigmentation.

The papers were recently presented to peers in the wound-care space at the [16th European Burns Association Congress](#) in Hannover Germany. The proceedings of the Congress appear in a September supplement to the *Annals of Burns and Fire Disasters*.

"The various researchers have been looking at the device usage for different indications, and in varying circumstances, but collectively these publications all give a positive read on the treatment power of ReCell®," said Avita Medical CEO Adam Kelliher. "These papers add to our clinical bibliography, and give us new insights into optimal methods and approaches for treatment using ReCell®, which will lead to increasingly better patient outcomes."

One paper, "[The Combination of Medical Needling and ReCell® for Repigmentation of Burn Scars](#),"¹ by Busch, K.H., et al, was published in the September issue of *Annals of Burns and Fire Disasters*, and assessed the outcomes of using the device on 20 patients who had deep 2nd and 3rd degree scars, in combination with medical needling. The cohort were followed up one year later to assess any pigmentation improvement. Overall, the study showed that medical needling in combination with ReCell® shows promise for repigmentation of burns scars.

"Taken together, the pigmentation ratings and objective measures indicate individual improvement in most of the study participants," concluded the researchers, from Malteser Hospital in Bonn, Germany. "The melanin increases seen 12 months after ReCell® treatment in the study group as a whole are statistically significant." In a second paper, titled "The Use of Recell® in a Regional Burn Service,"² by Tan, A. et al, researchers from Britain's Broomfield Hospital did a 3-year retrospective analysis of 48 patients, who have been treated with the device. They concluded that ReCell® had proven itself to be useful for pediatric scalds, for healing donor sites, and as a healing adjunct to autografts on large wounds.

In a third paper, "[The Role of ReCell® in Burns and Plastic Surgery Services: an Evidence-based Approach](#),"³ by Tan, A. et al, the same researchers performed a literature review of 42 papers using the device, covering burns, plastic surgery and repigmentation.

They concluded: “ReCell® does have promising potential in burn and plastic services. However, streamlining of its clinical indications through a recommended set of national guidelines is required to maximise its potential and cost effectiveness to the healthcare system.”

References

1. Busch, K.H., et al. “The Combination of Medical Needling and ReCell® for Repigmentation of Burn Scars.” Annals of Burns and Fire Disasters. Vol XXVIII, Supplement EBA, September 2015. Available at: http://www.medbc.com/annals/review/vol_28/num_3b/text/vol28n3bp60.pdf
2. Tan, A. et al. “The Use of Recell® in a Regional Burn Service.” Annals of Burns and Fire Disasters. Vol XXVIII, Supplement EBA, September 2015. Available at: http://www.medbc.com/annals/review/vol_28/num_3b/text/vol28n3bp423.pdf
3. Tan, A. et al. “The Role of ReCell® in Burns and Plastic Surgery Services: an Evidence-based Approach.” Annals of Burns and Fire Disasters. Vol XXVIII, Supplement EBA, September 2015. Available at: http://www.medbc.com/annals/review/vol_28/num_3b/text/vol28n3bp424.pdf

ABOUT RECELL®, REGENERCELL®, RENOVACELL®, AND RES™

ReCell® is Avita Medical’s unique proprietary technology that enables a clinician to rapidly create, at point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient’s skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.

ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita’s patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient’s own skin. The Company’s lead product, ReCell®, is used in the treatment of a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell® is patented, CE-marked for Europe, TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use. A pivotal U.S. trial is underway, with patient enrollment completion anticipated by the end of 2015. To learn more, visit www.avitamedical.com.

###

FOR FURTHER INFORMATION

Avita Medical Ltd
Adam Kelliher
Chief Executive Officer
Phone: +44 (0) 1763 269 772
akelliher@avitamedical.com

Avita Medical Ltd
Tim Rooney
Chief Financial Officer
Phone: + 1 (818) 356-9400
trooney@avitamedical.com

Avita Medical Ltd
Gabriel Chiappini
Company Secretary
Phone +61(0) 8 9474 7738
gabriel@laurus.net.au

USA
The Ruth Group
Lee Roth, Investor Relations
Kirsten Thomas, Public Relations
Phone: +1 (646) 536-7012 / +1
(508) 280-6592
lroth@theruthgroup.com
/ kthomas@theruthgroup.com

Australia
Monsoon Communications
Rudi Michelson
Investor Relations / PR
Phone: +61 3 9620 3333
rudim@monsoon.com.au